I'd say the carboplatin combo.... CytoDyn, Inc. i
Post# of 148122
CytoDyn, Inc. is a biotechnology company that has conducted clinical trials combining carboplatin with leronlimab to treat metastatic triple-negative breast cancer (mTNBC). In July 2021, CytoDyn announced promising preliminary results from the phase 1b/2 trial, which involved 30 patients. The FDA also granted CytoDyn fast track designation for leronlimab in 2019.